Denosumab and fracture risk in women with breast cancer - Author's reply. - Suppr

Suppr

超能文献

Denosumab and fracture risk in women with breast cancer - Author's reply.

作者信息

Gnant Michael

机构信息

Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.

出版信息

Lancet. 2015 Nov 21;386(10008):2057-2058. doi: 10.1016/S0140-6736(15)00975-7. Epub 2015 Nov 20.

DOI:10.1016/S0140-6736(15)00975-7

PMID:26700393

Abstract

摘要

相似文献

Denosumab and fracture risk in women with breast cancer - Author's reply.

Lancet. 2015 Nov 21;386(10008):2057-2058. doi: 10.1016/S0140-6736(15)00975-7. Epub 2015 Nov 20.

Denosumab and fracture risk in women with breast cancer.

Lancet. 2015 Aug 1;386(9992):409-10. doi: 10.1016/S0140-6736(15)61032-7. Epub 2015 May 31.

Denosumab and fracture risk in women with breast cancer.

Lancet. 2015 Nov 21;386(10008):2057. doi: 10.1016/S0140-6736(15)00974-5. Epub 2015 Nov 20.

Denosumab and fracture risk in women with breast cancer.

Lancet. 2015 Nov 21;386(10008):2056-2057. doi: 10.1016/S0140-6736(15)00973-3. Epub 2015 Nov 20.

In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures.

Ann Intern Med. 2015 Sep 15;163(6):JC11. doi: 10.7326/ACPJC-2015-163-6-011.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

Prospects of adjuvant RANKL inhibition in breast cancer?

Cell Death Dis. 2015 Nov 19;6(11):e1982. doi: 10.1038/cddis.2015.332.

[Inhibition of RANK ligand to treat bone metastases].

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835.

Denosumab. Limited efficacy in fracture prevention, too many adverse effects.

Prescrire Int. 2011 Jun;20(117):145-8.

Denosumab: in cancer treatment-induced bone loss.

BioDrugs. 2010 Dec 1;24(6):379-86. doi: 10.2165/11203310-000000000-00000.

引用本文的文献

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun.

Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.

Eur J Clin Pharmacol. 2017 May;73(5):517-523. doi: 10.1007/s00228-017-2210-x. Epub 2017 Feb 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Denosumab and fracture risk in women with breast cancer - Author's reply.

Lancet. 2015 Nov 21;386(10008):2057-2058. doi: 10.1016/S0140-6736(15)00975-7. Epub 2015 Nov 20.

Denosumab and fracture risk in women with breast cancer.

Lancet. 2015 Aug 1;386(9992):409-10. doi: 10.1016/S0140-6736(15)61032-7. Epub 2015 May 31.

Denosumab and fracture risk in women with breast cancer.

Lancet. 2015 Nov 21;386(10008):2057. doi: 10.1016/S0140-6736(15)00974-5. Epub 2015 Nov 20.

Denosumab and fracture risk in women with breast cancer.

Lancet. 2015 Nov 21;386(10008):2056-2057. doi: 10.1016/S0140-6736(15)00973-3. Epub 2015 Nov 20.

In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures.

Ann Intern Med. 2015 Sep 15;163(6):JC11. doi: 10.7326/ACPJC-2015-163-6-011.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

Prospects of adjuvant RANKL inhibition in breast cancer?

Cell Death Dis. 2015 Nov 19;6(11):e1982. doi: 10.1038/cddis.2015.332.

[Inhibition of RANK ligand to treat bone metastases].

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835.

Denosumab. Limited efficacy in fracture prevention, too many adverse effects.

Prescrire Int. 2011 Jun;20(117):145-8.

Denosumab: in cancer treatment-induced bone loss.

BioDrugs. 2010 Dec 1;24(6):379-86. doi: 10.2165/11203310-000000000-00000.

引用本文的文献

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun.

Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.

Eur J Clin Pharmacol. 2017 May;73(5):517-523. doi: 10.1007/s00228-017-2210-x. Epub 2017 Feb 10.